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Abstract
Background: The purpose of the study is to determine levels of total cholesterol (TC), low-density, and high-density
lipoprotein fractions of cholesterol (LDLc and HDLc), in patients with juvenile idiopathic arthritis (JIA), and relate those
to disease activity, overweight, and physical activity (PA), testing the hypothesis that the levels of cholesterol fractions
are associated with inflammation as well as with overweight and low PA.
Methods: Two hundred ten patients with JIA were included in this descriptive cross-sectional study. TC, LDLc, HDLc
were measured, and associations with clinical disease activity (JADAS27), biomarkers of inflammation (myelo-related
protein complex 8/14 (MRP8/14), C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR)), body mass index
(BMI), waist-to-height ratio (WtH ratio), and PA were explored.
Results: Mean values for TC, LDLc, and HDLc in the patients were within the normal range for Danish Children. HDLc
was negatively correlated with MRP8/14 (r = −0.343, CI −0.474 to −0.201, p < 0.0005) but was not related to overweight
or PA. Neither TC nor LDLc showed any association with inflammation, overweight, or PA. MRP8/14 correlated
positively with CRP, JADAS27 and WtH ratio (r = 0.277, CI 0.142 to 0.413, p = 0.001).
Conclusions: Levels of cholesterol fractions in patients with JIA were found within the normal range. Nonetheless, the
level of HDLc was negatively associated with the level of the inflammatory marker MRP8/14, which is in accordance
with the concept of inflammation as an important driver for premature development of atherosclerosis in JIA. WtH
ratio (a measure of central fatness) was not associated to HDLc, but to MRP8/14, suggestive of central fatness as an
additional driving factor for the chronic inflammation in JIA.
Keywords: Juvenile chronic arthritis, JIA, Cholesterol-fractions, HDL-cholesterol, LDL- cholesterol, MRP8/14, BMI,
Waist-to-height ratio, Premature atherosclerosis
Background
Juvenile idiopathic arthritis (JIA) is a longstanding inflam-
matory arthritis of unknown origin in a child below
16 years of age. In the Nordic European countries is found
an incidence of 15 per 100,000 children per year [1]. JIA
includes several clinical subtypes, probably of different
pathogenesis. The outcome in terms of functional ability
has changed greatly during the last two decades due to
progress in medical anti-inflammatory treatment; only few
patients nowadays become functionally impaired during
childhood or as young adults. However, a cure for JIA has
not been found, and less than half of the patients achieve
full and permanent remission [2–4].
Premature development of atherosclerosis is a well de-
scribed feature of several chronic inflammatory diseases,
including rheumatoid arthritis (RA) [5–7]. The clinical
similarity between RA and JIA has given rise to several
studies of the vasculature of patients with JIA, leaving
no doubt that also JIA is associated with early signs of
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subclinical atherosclerosis [8, 9]. Persisting systemic in-
flammation may be a primary contributor, but other
known risk factors for development of atherosclerosis,
such as dyslipidemia, obesity, and sedentary behavior
may contribute as well, and should be addressed prophy-
lactically along with anti-inflammatory treatment.
In the general population, a high level of total choles-
terol (TC), with a high fraction of low-density lipoprotein
cholesterol (LDLc) and a low fraction of high-density lipo-
protein cholesterol (HDLc), is associated with develop-
ment of atherosclerosis [10]. Observational studies show
that patients with RA have a nearly 50 % increased risk of
experiencing clinically significant cardiovascular events
compared to the general population [6, 7], but have a
cholesterol profile different from the atherogenic profile
described above. It is generally accepted that untreated
RA, with the highest risk of clinically important athero-
sclerosis, is associated with low levels of HDLc and LDLc
[10–12]. This is intriguing, as lipid deposits in the arterial
intima are the hallmark of atherosclerosis.
Most previous studies of cholesterol fractions in JIA
reported decreased levels of HDLc, while the level of
LDLc varies between studies; a consistent pattern in re-
gard to concomitant clinical or biochemical markers of
inflammation is not evident in the literature [13–19].
Overweight and obesity in children and adolescents is
typically associated with increased TC and decreased
HDLc [20, 21]. The worldwide rise in the incidence of
overweight and obesity reported in children and adoles-
cents could also occur among patients with JIA and may
also contribute to changes in cholesterol fractions seen
in children with JIA [19].
A low level of physical activity (PA) may per se be as-
sociated with a raised level of TC [22]. A low level of PA
in patients with JIA, as found in a recent study of PA in
children with JIA [23], may possibly contribute to the di-
vergent findings regarding lipid fractions in JIA.
The purpose of this study is to examine the levels in
the blood of the cholesterol fractions (TC, LDLc, and
HDLc), in children and adolescents with JIA, testing the
hypothesis that the cholesterol fractions are correlated
with inflammation as well as with overweight and PA.
Methods
Design
This is a descriptive cross-sectional study of blood choles-
terol fractions, disease characteristics, anthropometrics,
and objectively measured PA in patients with JIA. The
patient population and level of PA was recently de-
scribed in detail [23].
Patients
All patients with JIA, 7 to 20 years of age, followed during
a period from May 2011 to May 2013 at a population
based out-patient specialized center for pediatric rheuma-
tology covering Copenhagen and the eastern part of
Denmark, were invited to participate. No one had signifi-
cant chronic conditions other than JIA, especially no
known conditions connected with dyslipidemia, and no
patients received corticosteroid at the time of investiga-
tion, or had had recent intra-articular injection of cortico-
steroids. The patients were asked about family history of
cardiovascular disease.
The patients were diagnostically sub-grouped in accord-
ance with ILAR criteria [24].
Of 260 eligible patients, 50 declined to participate for
logistical or social reasons not related to their disease.
Forty-four patients declined accelerometer monitoring
but accepted clinical evaluation and blood tests. Thus a
total of 210 patients were available for clinical evaluation
and analyses of inflammatory markers and cholesterol
fractions in the blood; 166 accepted to participate in the
whole investigation, including monitoring with acceler-
ometer, which was done in the weeks after clinical
assessment and blood tests. Of these, 133 patients
returned accelerometer monitoring results of a suffi-
cient quality for evaluation as defined below (Fig. 1).
Clinical valuation of disease activity
All participants were assessed clinically by a pediatrician
experienced in pediatric rheumatology and not involved
in the investigation. The patients were seen as part of a
routine control, no one was seen because of flare. Disease
activity was described by a composite score, Juvenile
Arthritis Disease Activity Score including evaluation of
27 joints (JADAS27) [25, 26]: i) number of joints with
active inflammation: cervical spine, elbows, wrists,
metacarpophalangeal joints 1–3, proximal interphalan-
geal joints 1–5, hips, knees, ankles, ii) global disease
scoring by physician, iii) global disease scoring by pa-
tient or parent according to age, and iv) truncated
erythrocyte sedimentation rate (tESR). JADAS27 is
measured on a scale from 0–57.
Global disease activity was scored using a visual analog
scale (VAS) from 0 (no sign of disease) to 10 (maximal
burden of disease) by the physician and the patients/par-
ents (according to age). Remission was assessed accord-
ing to Wallace criteria [27].
Markers of inflammation in blood
C-reactive protein (CRP) was measured (Roche/Hitachi
cobas c-system, Mannheim, Germany) by turbidimetry
after precipitation of agglutinated antibodies to CRP; the
lower detection limit is 0.15 mg/l. Myelo-related-protein
complex 8/14 (MRP8/14) was measured quantitatively in
serum by use of a commercial ELISA kit (Bühlmann
Laboratories AG, Schönenbuch, Switzerland) according
to the manufacturer’s instructions. The principle is a
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sandwich technique with a monoclonal antibody specific
to the MRP8/14 heterodimeric and polymeric com-
plexes. Detection limit is < 0.4 mikrogram/ml. Analysis
of MRP8/14 was done on serum of blood samples frozen
immediately after separation and stored at −80°. ESR
was used in the JADAS27 truncated (tESR) according to
the formula given by Consolaro et al. [25]: after convert-
ing ESR values of ≤ 20 mm/h to 0 and ESR ≥ 120 to 120,
tESR was calculated as (ESR (mm/h) - 20)/10 leaving a
score of tESR from 0 to 10.
Treatment
All the patients were either in treatment with metho-
trexate (MTX) and/or biological DMARDS: TNF-α-
inhibitors, IL-6 receptor inhibitor (tocilizumab) or T-cell
co-stimulation inhibitor (abatacept), or solely by regular
intra-articular injections of corticosteroid.
Anthropometry
Overweight and obesity was assessed by BMI and waist-
to-height ratio (WtH ratio).
Weight was measured with light clothing to the near-
est 0.1 kg and height without shoes to the nearest
0.1 cm. BMI was calculated as weight/squared height,
and standard deviation score (BMI SDS) was calculated
by comparison with Danish age and gender specific BMI
values, transformed into normal distribution [28]. Waist
circumference was measured with a non-stretchable
tape, after expiration in a normal breathing rhythm,
midway between the lower rib margin and the iliac crest.
Pubertal stage (Tanner stage), was assessed by the pa-
tients or parents according to pictograms.
Blood pressure
Blood pressure was measured with a Dinamap paediatric
monitor (model XL, Critikon, Inc, Tampa, FL, USA) with
the patient in a sitting position. The last two measure-
ments out of three at each arm were used for calculation
a mean systolic and a mean diastolic blood pressure. As
blood pressure increases with age and is correlated to
gender and height, the measured blood pressures (sys-
tolic or diastolic) were classified as normal (<90-percent-
ile), pre-hypertensive (between 90 and 95 percentile) or
hypertensive (>95 percentile) according to calculated
percentiles in corresponding subgroups in data from a
large group of normal American children of different
age, sex and height, weight, and race [29].
Lipids
TC, LDLc, and HDLc were measured in plasma using
Roche modular by enzymatic colorimetry (Cobas c-system,
Roche Diagnostics, Mannheim, Germany).
Blood lipids were measured in a non-fasting state, as
in the Danish pediatric reference material [30].
Accelerometry
Volume and pattern of PA was assessed during seven
days by an accelerometer, ActiGraph model GT1M
(ActiGraph Inc., Pensacola, FL, USA) a small, portable
device worn fastened around the waist with an elastic
band. The device measures vertical acceleration of the
body and the reliability in measuring PA has been docu-
mented [31]. The device cannot be used during swimming
or bathing. Reasons for not wearing the device and the
time spent without it were noted, as was time spent on
horseback riding and cycling, since these physical activities
are not captured accurately by accelerometry [32].
The raw data were converted, after correction for non-
wear time, by the ActiGraph software to i) mean counts
per minute (cpm), a measure of average PA during total
time of measurement, and ii) minutes per day spent in
high PA (more than 3000 cpm), a cut-point routinely
Fig. 1 Included patients
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used by others, and iii) sedentary time assessed as aver-
age number of periods per day of more than 10 min with
an activity of more than zero but less than 100 cpm.
Only data collected during a minimum of 10 h per day
for three days were considered reliable in assessing PA
[22]. Periods of more than 10 min of zero count were
considered as periods of “non-wear”.
Primary endpoints
Disease activity (JADAS, CRP, MRP8/14), anthropometry
(BMI, WtH ratio), and PA (cpm, sedentary time, high ac-
tivity) correlated to TC, LDLc, and HDLc.
Secondary endpoints
Correlations between cholesterol fractions and subgroup
of JIA, treatment, disease duration, hypertension, gender,
or Tanner stage were considered of explorative value.
Statistical analyses
Summary statistics mean and standard deviation (SD),
median and range, or numbers with percentages, were
chosen as descriptive measures.
Associations were tested by T-test, Pearson bivariate
correlation analyses, and analysis of variance (one-way
ANOVA). As a significant correlation was found between
MRP8/14 and WtH ratio and HDLc, we performed a
multiple linear regression analysis. All variables were log10
transformed, because of a non-normal distribution. Spear-
man’s rho is calculated in analyses of JADAS, which could
not be transformed to a normal distribution.
Significance (p) is given as two-tailed and with α = 0.004
after Bonferroni correction since we performed 12 inde-
pendent tests on our primary endpoints: disease activity
(JADAS/CRP), MRP8/14, anthropometry (BMI, WtH ratio),
and PA (cpm, sedentary time, high activity) correlated to
TC, LDLc, HDLc. Secondary endpoints were not corrected
for multiple testing, as they were regarded as explorative.
All analyses were done in SPSS19, IBM Corp. IBM
SPSS Statistics for Windows, Version 19.0. Armonk, NY:
IBM Corp. USA, or in Excel 2010, Microsoft Corp. Red-
mond WA, USA.
Results
Patients, disease activity, and cholesterol fractions
The 210 included patients are described by gender, age,
Tanner stage, anthropometrics, JIA subgroup, treat-
ment, and disease duration (Table 1) and broadly simi-
lar to the features of the Nordic JIA cohort [3]. Mean
age was 14.4 years, 58 % being in full puberty. Most pa-
tients were in treatment with biological DMARDs
(68 %), by far most frequently with TNF-α inhibitors.
Four patients (1.9 %) were in complete remission off
medication, the treatment being withdrawn within the
last 6 months. Seven of our patients had a family
history of cardiovascular disease; the level of HDLc in
these patients did not differ from the rest.
The group of patients that refused participation (no.
50) was comparable with the 210 participating pa-
tients with regard to age, gender and subgroup of
JIA. The group that participated only partly and the
group that participated fully were comparable also in
the distribution of BMI and actual disease activity
(data not shown).
Table 1 Descriptive characteristics of the patients
Total number 210
Females/males 149 (71 %)/61 (29 %)
Age (years) Mean 14.4 (SD 3.40)
Median 15.00 (Range 7–21)
Height (m) Mean 1.60 (SD 0.15)
Median 1.62 (Range 1.14–1.87)
Weight (kg) Mean 52.8 (SD 15.9)
Median 53.8 (Range 18.5–97.0)
BMI SDS a Mean 0.4 (SD 1.17)
Median 0.50 (Range −3.2–3.6)
Waist-to-height ratio (163 patients) Mean 0.44 (SD 0.04)
Median 0.43 (Range 0.35–0.62)
Tanner Stadium 121 (57.6 %) in Tanner Stage 5
JIA subgroup:
- Systemic 6 (2.9 %)
- Persisting Oligoarticular 65 (31 %)
- Polyarticular, RF negative 53 (25 %)
- Polyarticular, RF positive 8 (3.8 %)
- Psoriasis associated 21 (10.0 %)
- Enthesitis associated 56 (26.7 %)




- HLA-B27 positive 40 (19 %)
Treatment
- Methotrexate 40 (19 %)
- Biologics +/− Methotrexate: 142 (68 %)
either TNF-α inhibitors 130
or IL-6 receptor inhibitor 4
or T-cell co-stim inhibitor CTLA-4-Ig 8
- Solely by intra-articular injections 13 (6.2 %)
- None 10 (4.8 %)
- No information 4 (1.9 %)
Disease duration b in years Mean 6.1 (SD 3,7)
Median 5.2 (Range 0.5–17.3)
Complete remission off medication 4 (1.9 %)
Summary statistics: Number with percentage in brackets, mean with SD in
brackets, and median with range in brackets
aBMI SDS Body mass Index Standard Deviation Score, gender and age adjusted
bDisease duration = duration of symptoms
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Data on clinical disease activity and markers of inflam-
mation in the blood are presented in Table 2. Numbers
of inflamed joints, physician global VAS scores, ESR and
CRP all indicate a general low level of disease activity in
the patients.
Mean values for TC, LDLc, and HDLc were all within
the normal range for Danish Children [30] (Table 3).
Correlation between primary and secondary outcomes
and TC, HDLc, or LDLc
We found a significant negative correlation between
HDLc and the inflammatory marker MRP8/14 with a
Pearson correlation coefficient (r) of – 0.343, (p < 0.0005),
while the correlation between HDLc and CRP and WtH
ratio did not reach significance at the Bonferroni cor-
rected level. HDLc and JADAS27 did not correlate signifi-
cantly and we found no significant correlations between
LDHc or TC and MRP8/14 or any other marker of inflam-
mation. Neither TC nor cholesterol fractions correlated
significantly with subgroups of JIA, treatment, duration of
disease, gender, or Tanner stage. (Table 4).
Correlations between inflammatory markers
MRP8/14 correlated positively and significantly with CRP
(r = 0.480, p < 0.0005) and with JADAS27 (rho = 0.221,
p = 0.006) (Table 5). To our knowledge no studies
provide normal values of MRP8/14 in children.
Overweight and obesity and correlation to cholesterol
and inflammation
Thirty percent of the patients had a BMI SDS above 1
SD, and 7.6 % had a BMI SDS above 2 SD compared to
the Danish age and gender adjusted reference material
[28]. Only 5 patients had a BMI SDS below 2 SD.
Prehypertension defined as a diastolic or systolic
blood-pressure between the 90. and 95. percentile, was
seen in 17 % of the patients with an unsurprising associ-
ation to BMI but with no correlation to MRP8/14.
Neither BMI nor WtH ratio showed a significant correl-
ation to TC, HDLc, or LDLc (Table 4). As a significant cor-
relation was found between WtH ratio and MRP8/14
(Table 6) we performed a multiple linear regression analysis
of HDLc as dependent on the independent variables WtH
ratio and MRP8/14. WtH ratio did not add significantly to
the prediction of HDLc (β = −0.069, p = 0.395) while
MRP8/14 remained significant (β = −0.330, p < 0.0005)
(Table 7).
We found no association between central fatness, mea-
sured by WtH ratio, and medication (data not shown).
PA and correlations to cholesterol
Neither TC nor LDLc nor HDLc cholesterol fractions
correlated with time spent on sedentary PA or with high
PA (Table 4).
Discussion
In our group of patients with JIA most had minimal
disease activity, and TC, HDLc and LDLc were found
within the normal range. Nevertheless, HDLc showed a
negative correlation with MRP8/14, a sensitive marker
of inflammation. In contrast, neither TC nor LDLc
showed any significant correlation to markers of
inflammation.
Our finding of a significant correlation between HDLc
and a marker of inflammation is in agreement with two
previous findings in JIA [14, 15]; both found a negative
correlation between HDLc and the inflammatory marker
CRP. Furthermore a study by Shen et al. [33] on 58
patients with JIA showed a significant increase in HDLc
in parallel with a decrease in CRP in 31 patients with in-
active disease after 18 months of anti-inflammatory
treatment; the level of LDLc did not change. In contrast,
another intervention study of patients with active JIA
[34] showed a more traditional atherogenic lipid profile,
with an increased total LDLc and normal HDLc at base-
line. After 12 months of anti-inflammatory treatment,
the investigators found a large decline in inflammatory
markers concomitant with a relatively small decline in
LDLc and no change in HDLc.
Most of the patients included in our study had low
disease activity according to JADAS27 score, CRP, and
ESR. In JIA with low to moderate disease activity, clas-
sical biomarkers of inflammation (CRP, ESR) are most
often not increased. In order to capture a possible asso-
ciation between cholesterol fractions and low grade
inflammation, we also measured MRP8/14. MRP 8 (the
Table 2 Markers of disease activity
Number of inflamed joints (0–27) Mean 1.17 (SD 2.26)
Median 0.0 (Range 0–24)
Physician global VAS (0–10) Mean 1.13 (SD 1.28)
Median 1.00 (Range 0–6.5)
Patient/parent global VAS (0–10) Mean 1.67 (SD 2.05)
Median 0.8 (Range 0–10)
ESR (mm/h) Mean 10.4 (SD 7.8)
Median 9.0 (Range 1–58)
Truncated ESR (tESR) (mm/h) Mean 0.08 (SD 0.40)
Median 0.00 (Range 0–3,8)
CRP (mg/l) Mean 1.98 (SD 3.64)
Median 0.61 (Range 0.16–31.0)
JADAS27 (0–57) a Mean 4.2 (SD 4.1)
Median 3.2 (Range 0–21)
MRP8/14 (μg/ml) Mean 1.34 (SD 1.22)
Median 1.03 (Range 0.18–13.75)
Tendinitis and/or entesitis 47 (22.4 %)
Summary statistics: Number with percentage in brackets, mean with SD in
brackets, and median with range in brackets
aJADAS27 (0–57) (169 patients): a composite score of: number of joints with
active disease (max 27), Physician global VAS, patient/parent global VAS and
truncated ESR (tESR)
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same as S100A8) and 14 (S100A9) are calcium-binding,
potent pro-inflammatory proteins produced locally by
activated phagocytic myeloid cells. MRP8/14 is released
as a stable heterodimer into the circulation, where it acts
as a pro-inflammatory mediator, promoting activation of
inflammatory cells through binding to Toll-like recep-
tors resulting in the production of cytokines such as
interleukin-1β and IL-6 that, unimpeded, amplify and
perpetuate the inflammation [35, 36]. The MRP8/14
dimer is measurable in the synovial fluid and the blood,
and is correlated with measures of disease activity and
risk of relapse after stopping anti-inflammatory medica-
tion in JIA [37–40]. While pro-inflammatory cytokines
in JIA, such as TNF- α, are easily degraded and found
at low concentration in the blood, MRP8/14 is a more
abundant and more stable protein also at room
temperature. In this study, MRP8/14 correlated signifi-
cantly with JADAS27 and CRP.
Table 3 Cholesterol fractions and triglyceride
Danish pediatric reference intervals [30]
Total cholesterol (TC) mmol/l Mean 3.94 (SD 0.72) 2.74–5.33
High Density Lipoprotein fraction of cholesterol (HDLc) mmol/l Mean 1.48 (SD 0.35) 1.0–2.1
Low Density Lipoprotein fraction of cholesterol (LDHc) mmol/l Mean 2.16 (SD 0.58) 1.1–3.6
Summary statistics: Number with percentage in brackets, mean with SD in brackets
Table 4 Associations between cholesterol fractions and disease characteristics, fatness, and physical activity P values with correlation
coefficients, and 95 % confidence interval in brackets
Patients TC mmol/l HDLc mmol/l LDLc mmol/l
Gender T-test 0.05 0.19 0.12
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Counts per minute (cpm) (133 patients)
Bivariate correlation
0.23 0.25 0.33
Sedentary time (minutes/day) (133 patients)
Bivariate correlation
0.23 0.61 0.11
High activity (minutes/day) (133 patients)
Bivariate correlation
0.15 0.21 0.17
TC total cholesterol, HDLc high density fraction of cholesterol, LDLc low density fraction of cholesterol
*Significance (p) is given as two-tailed and α selected after Bonferoni correction as 0.004 (12 independent tests)
aTreatment: Methotrexate versus TNF-α inhibitor versus IL-6 receptor inhibitor versus T-cell co-stimulation inhibitor CTLA-4-Ig
bJADAS27 (0–57): a composite score of: number of joints with active disease (max 27), Physician global VAS, patient/parent global VAS and truncated ESR (tESR)
All parametric bivariate correlations have been performed after log10 transformation
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The aforementioned association between inflammation
and low levels of HDLc in active RA has been demon-
strated in observational studies; no clear causality has
been found. However, HDLc particles are important
transporters of excess cholesterol from cells, e.g. macro-
phages in the arterial intima, to the liver (“reverse chol-
esterol transport”) [41]. Insufficient clearance of
cholesterol could partly explain why atherosclerosis is
seen in RA patients. Not only the level of HDLc, but also
its function may be influenced by inflammation. Upon
treatment of patients with RA with an anti-IL-6 R in-
hibitor, McInnes et al. [42] found a decrease in the bind-
ing of the acute phase reactant, serum amyloid A to
HDL particles, as well as an increase in paraoxonase, an
antioxidant enzyme connected to HDLc. Thus, HDL
particles were reverted from a dysfunctional and pro-
inflammatory state to a normal cholesterol-carrying state
after anti-inflammatory treatment.
Overweight, defined as BMI SDS above 1, was seen in
30 % of our patients when compared to the Danish gen-
der and age adjusted reference material [28]; neither
BMI nor WtH ratio correlated with cholesterol fractions.
However, we found a positive correlation between WtH
ratio and MRP8/14. In both genders and regardless of
age, WtH ratio is associated not only with BMI but also,
independently of BMI, with other risk factors for devel-
opment of cardiovascular disease, like hypertension and
dyslipidemia, [43, 44]. WtH ratio reflects central, visceral
fatness, which is considered the place of origin for devel-
opment of the low-grade inflammation known to be as-
sociated with overweight and obesity. Central fatness
may thus influence cardiovascular health in children
with JIA by contributing to a continuing low-grade
inflammation.
The lipids are measured in a non-fasting state. Older
investigations are primarily built on lipids measured in a
fasting state, but blood sampling after overnight fasting
pose a practical problem in investigations of children liv-
ing far from laboratories doing the blood sampling.
Besides, children are most often in a non-fasting state,
and thus the non-fasting levels of lipids may have the
highest relevance as risk factors for endothelial damage
and cardiovascular disease. In adults, TC and HDLc vary
less than 2 % with fasting time; LDHc varies up to 10 %
[45]. The Danish Pediatric reference intervals for lipids
are based on blood samples taken from non-fasting chil-
dren and adolescents.
Although the correlation between HDLc and MRP8/
14 was highly significant in our study, the correlation
coefficient was only moderate as in the study by Shen
et al. [33], indicating influence by other factors than
MRP8/14. In a review on PA and cardiovascular risk fac-
tors in children, Andersen et al. [46] suggested a positive
effect of PA on HDLc, with no effect on LDLc and TC.
Our study does not support this, as we found no signifi-
cant correlations between PA and HDLc or LDLc. How-
ever, we did not measure fitness. Fitness is built up by
regular PA and may thus be a better marker of general
health and have a more significant influence on lipids in
the blood, than the more sporadic PA that we were able
to measure [47].
The present study has other important limitations. As
some of the subgroups had a low number of patients, we
have not performed any analysis concerning subgroups
of JIA. Considering JIA as a uniform group, especially
including sJIA, characterized by high levels of inflamma-
tory mediators, may have inflated the found correlation
between MRP8/14 and HDLc. Likewise we cannot ex-
clude that hidden confounders correlated to the patho-
genesis of specific subtypes, and not related to disease
activity per se, may have influenced the findings. We did
not find any correlation between treatment regimes and
the cholesterol fractions, but we did not look at the spe-
cific doses of medicine, which could be of importance,
as some medicine may have specific effect on the choles-
terol fractions besides the anti-inflammatory effect. Most
of our patients received effective anti-inflammatory
treatment and had low disease activity. Looking at the
level of HDLc before and during anti-inflammatory
treatment would be important in future studies.
A cross-sectional descriptive study is at best able to
demonstrate associations; causality must be tested in
subsequent controlled longitudinal trials. In a setting of
updated clinical and biological information, correlations
can, nevertheless, have immediate clinical relevance. A
strength of our study is that we have looked at a large
community-based, representative, and well-described
group of patients and have used a sensitive marker of in-
flammation (MRP8/14).
At present there is evidence that patients with JIA
have an increased risk for early development of subclin-
ical atherosclerosis [8, 9]. No long-term follow-up stud-
ies of adults with JIA have yet shown an increased risk
Table 5 Correlation between the inflammatory marker MRP8/14









(95 % CI 0.064–0.373)
p = 0.006
Table 6 Pearson correlation between inflammatory markers
(MRP8/14 and CRP) and markers of fatness (waist-to-height
ratio and BMI SDS)
MRP8/14 CRP
Waist-to-height ratio (WtH ratio) r = 0.277 p = 0.001 r = 0.16 p = 0.051
BMI SDS r = 0.128 p = 0.082 r = 0.128 p = 0.081
All variables have been log10 transformed
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of clinically important cardiovascular events in early
adult life, underscoring that development of atheroscler-
osis is a complex process. Availability of effective anti-
inflammatory medication and a strategy favoring an early
and aggressive use of this may well have a beneficial ef-
fect also on vascular health, but adverse lifestyle factors
should still be taken into consideration.
Conclusions
Levels of cholesterol fractions in patients with JIA were
found within the normal range. Nonetheless, the level of
HDLc was negatively associated to the level of the in-
flammatory marker MRP8/14, which is in accordance
with the concept of inflammation as an important driver
for premature development of atherosclerosis in JIA.
WtH ratio (a measure of central fatness) was not asso-
ciated to HDLc, but to MRP8/14, suggestive of central
fatness as an additional driving factor for the chronic
inflammation in JIA.
Key messages
Even in clinically well-controlled JIA, the level of HDLc
is negatively associated to the level of the inflammatory
marker MRP8/14.
Central fatness correlates independently to the level of
MRP 8/14 and may thus exacerbate the chronic inflam-
mation in JIA.
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